Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion criteria

• Inclusion criteria for allogeneic hematopoietic stem cell transplantation shall be implemented in accordance with the regulations of the transplant center at the study site;
• Patients undergoing allogeneic hematopoietic stem cell transplantation with any of the following high-risk factors for EBV infection:

• EBV-DNA is positive in the recipient's or donor's serum, whole blood, PBMC or sorted cells before allogeneic hematopoietic stem cell transplantation;
• EBV-DNA is positive in the recipient's whole blood, PBMC or sorted cells after allogeneic hematopoietic stem cell transplantation, but EBV-DNA in plasma is negative;
• Allogeneic hematopoietic stem cell transplantation is performed due to treatment of EBV infectious diseases, including but not limited to: EBV-related lymphoma, chronic active EBV infection, EBV-related lymphoproliferative disorders, etc.;
• There is a history of EBV infection in the past, and allogeneic hematopoietic stem cell transplantation is required due to other malignant diseases.
• No age or gender restrictions;
• The subject and the guardian understand and sign the informed consent form.

Exclusion criteria

• The exclusion criteria for allogeneic hematopoietic stem cell transplantation shall be implemented in accordance with the regulations of the transplant center at the study site;
• Exclusion criteria before infusion of JYEST cell injection:

• Severe kidney disease (creatinine clearance rate less than 50% of the normal reference value for the same age group);
• Severe liver disease (TBil > 2.0×ULN; ALT and AST > 3.0×ULN);
• Severe acute infection (opportunistic infection);
• Expected survival period less than 6 weeks;
• Malnutrition (weight ≤ 10th percentile for the same age group, or serum albumin ≤ 3.0 g/dL);
• ECOG score > 2.